BlackRock
ADPT icon

BlackRock’s Adaptive Biotechnologies ADPT Stock Holding History

BlackRock’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325M Buy
15,139,159
+1,836,134
+14% +$28.1M ﹤0.01% 1507
2026
Q1 		$185M Sell
13,303,025
-30,534
-0.2% -$486K ﹤0.01% 1719
2025
Q4 		$217M Sell
13,333,559
-24,418
-0.2% -$399K ﹤0.01% 1627
2025
Q3 		$200M Sell
13,357,977
-308,873
-2% -$3.76M ﹤0.01% 1661
2025
Q2 		$159M Buy
13,666,850
+1,437,057
+12% +$13.1M ﹤0.01% 1753
2025
Q1 		$90.9M Buy
12,229,793
+108,947
+0.9% +$837K ﹤0.01% 2049
2024
Q4 		$72.7M Buy
12,120,846
+188,005
+2% +$1.04M ﹤0.01% 2244
2024
Q3 		$61.1M Buy
11,932,841
+268,839
+2% +$1.17M ﹤0.01% 2356
2024
Q2 		$42.2M Buy
11,664,002
+473,883
+4% +$1.5M ﹤0.01% 2518
2024
Q1 		$35.9M Sell
11,190,119
-231,435
-2% -$895K ﹤0.01% 2647
2023
Q4 		$56M Sell
11,421,554
-163,554
-1% -$746K ﹤0.01% 2410
2023
Q3 		$63.1M Buy
11,585,108
+102,521
+0.9% +$678K ﹤0.01% 2263
2023
Q2 		$77M Sell
11,482,587
-285,854
-2% -$2.13M ﹤0.01% 2220
2023
Q1 		$104M Sell
11,768,441
-605,756
-5% -$5.34M ﹤0.01% 1990
2022
Q4 		$94.5M Buy
12,374,197
+2,254,788
+22% +$17.5M ﹤0.01% 2035
2022
Q3 		$72.1M Buy
10,119,409
+1,098,301
+12% +$10.3M ﹤0.01% 2171
2022
Q2 		$73M Buy
9,021,108
+3,054,607
+51% +$26.9M ﹤0.01% 2236
2022
Q1 		$82.8M Buy
5,966,501
+496,512
+9% +$7.81M ﹤0.01% 2256
2021
Q4 		$153M Sell
5,469,989
-120,237
-2% -$3.69M ﹤0.01% 1922
2021
Q3 		$190M Buy
5,590,226
+270,369
+5% +$9.78M 0.01% 1753
2021
Q2 		$217M Buy
5,319,857
+416,812
+9% +$16.2M 0.01% 1699
2021
Q1 		$197M Sell
4,903,045
-40,894
-0.8% -$2.21M 0.01% 1748
2020
Q4 		$292M Sell
4,943,939
-366,973
-7% -$18.9M 0.01% 1326
2020
Q3 		$258M Sell
5,310,912
-303,696
-5% -$12.8M 0.01% 1185
2020
Q2 		$272M Buy
5,614,608
+653,776
+13% +$23.8M 0.01% 1116
2020
Q1 		$138M Buy
4,960,832
+1,802,283
+57% +$50.3M 0.01% 1424
2019
Q4 		$94.5M Buy
3,158,549
+1,260,622
+66% +$36.2M ﹤0.01% 1997
2019
Q3 		$58.6M Buy
1,897,927
+1,236,944
+187% +$50.5M ﹤0.01% 2198
2019
Q2 		$31.9M Buy
+660,983
New +$29.3M ﹤0.01% 2581

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock's ADPT Position: Q2 2026 in Review

BlackRock increased its Adaptive Biotechnologies (ADPT) stake by 14% in Q2 2026, buying an estimated $28.1M and bringing the position to 15,139,159 shares worth $325M. The position accounts for ﹤0.01% of the portfolio, ranked #1507.

BlackRock first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • BlackRock held 15,139,159 shares of Adaptive Biotechnologies worth $325M as of Q2 2026.
  • BlackRock bought 1,836,134 Adaptive Biotechnologies shares in Q2 2026, an estimated $28.1M.
  • Adaptive Biotechnologies made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1507 holding.
  • BlackRock first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.